- Home
- IOVA vs UTL Comparison
IOVA vs UTL Comparison
Compare IOVA & UTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOVA
- UTL
- Stock Information
- Founded
- IOVA 2007
- UTL 1984
- Country
- IOVA United States
- UTL United States
- Employees
- IOVA N/A
- UTL N/A
- Industry
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- UTL Power Generation
- Sector
- IOVA Health Care
- UTL Utilities
- Exchange
- IOVA Nasdaq
- UTL Nasdaq
- Market Cap
- IOVA 771.4M
- UTL 842.0M
- IPO Year
- IOVA N/A
- UTL N/A
- Fundamental
- Price
- IOVA $1.88
- UTL $51.52
- Analyst Decision
- IOVA Buy
- UTL Hold
- Analyst Count
- IOVA 10
- UTL 1
- Target Price
- IOVA $12.22
- UTL $55.00
- AVG Volume (30 Days)
- IOVA 10.4M
- UTL 71.7K
- Earning Date
- IOVA 08-07-2025
- UTL 08-05-2025
- Dividend Yield
- IOVA N/A
- UTL 3.47%
- EPS Growth
- IOVA N/A
- UTL N/A
- EPS
- IOVA N/A
- UTL 2.93
- Revenue
- IOVA $212,679,000.00
- UTL $486,900,000.00
- Revenue This Year
- IOVA $86.62
- UTL $16.37
- Revenue Next Year
- IOVA $69.95
- UTL $5.20
- P/E Ratio
- IOVA N/A
- UTL $17.70
- Revenue Growth
- IOVA 11070.12
- UTL N/A
- 52 Week Low
- IOVA $1.64
- UTL $51.10
- 52 Week High
- IOVA $12.51
- UTL $63.52
- Technical
- Relative Strength Index (RSI)
- IOVA 47.47
- UTL 39.34
- Support Level
- IOVA $1.68
- UTL $51.12
- Resistance Level
- IOVA $2.02
- UTL $52.25
- Average True Range (ATR)
- IOVA 0.11
- UTL 1.01
- MACD
- IOVA 0.03
- UTL 0.04
- Stochastic Oscillator
- IOVA 61.42
- UTL 9.46
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
About UTL UNITIL Corporation
Unitil Corp is a holding company, through its subsidiaries it is engaged in the local distribution of electricity and natural gas throughout its service territories in the states of New Hampshire, Massachusetts, and Maine. The Company has two operating and reportable segments: Utility Electric Operations and Utility Gas Operations. Majority of revenue is gained from Electric Segment.